ScoreWhy is NovoCure Ltd. ?
1
Flat results in Jun 25
- NET PROFIT(9M) At USD -139.43 MM has Grown at -26.18%
- DEBT-EQUITY RATIO (HY) Highest at -61.18 %
2
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -32.69%, its profits have risen by 11.3%
3
Rising Promoter Confidence
- Promoters have increased their stake in the company by 0.61% over the previous quarter and currently hold 0.93% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
4
Underperformed the market in the last 1 year
- Even though the market (S&P 500) has generated returns of 12.33% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -32.69% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to NovoCure Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is NovoCure Ltd. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
NovoCure Ltd.
-61.46%
-0.53
76.96%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
9.03%
EBIT Growth (5y)
-288.14%
EBIT to Interest (avg)
-88.42
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.76
Sales to Capital Employed (avg)
0.56
Tax Ratio
26.48%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
12.06%
ROE (avg)
0.63%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.24
EV to EBIT
-9.77
EV to EBITDA
-10.51
EV to Capital Employed
18.60
EV to Sales
2.61
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-190.50%
ROE (Latest)
-45.10%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
NET PROFIT(HY)
Higher at USD -74.46 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 8.15 times
-3What is not working for the Company
NET PROFIT(9M)
At USD -139.43 MM has Grown at -26.18%
DEBT-EQUITY RATIO
(HY)
Highest at -61.18 %
Here's what is working for NovoCure Ltd.
Net Profit
Higher at USD -74.46 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Debtors Turnover Ratio
Highest at 8.15 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Depreciation
Highest at USD 3.44 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for NovoCure Ltd.
Debt-Equity Ratio
Highest at -61.18 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
